Table 3.
Syphilis, gonorrhoea and chlamydia testing in national PrEP guidance documents retrieved, by country income level
| Syphilis screening | HIC (%) n=30 |
LMIC (%) n=39 |
| Recommended lab-based test type | ||
| Serological tests (non-specified) | 14/30 (47) | 5/39 (13) |
| Treponemal plus non-treponemal | 4/30 (13) | 13/39 (33) |
| Non-treponemal test only | 2/30 (7) | 7/39 (18) |
| Treponemal test only | 0/30 (0) | 2/39 (5) |
| Type not specified | 10/30 (33) | 12/39 (31) |
| Recommended rapid test type | ||
| Single treponemal | 0/30 (0) | 10/39 (26) |
| Dual HIV/syphilis (treponemal) | 0/30 (0) | 2/39 (5) |
| Recommended screening frequency | ||
| Every 3 months | 19/30 (63) | 21/39 (54) |
| Every 3–6 months | 5/30 (17) | 3/39 (8) |
| Every 6 months | 5/30 (17) | 7/39 (18) |
| Other | 1/30 (3) | 3/39 (8) |
| Frequency not specified | 0/30 (0) | 5/39 (13) |
| NG/CT screening |
HIC (%)
n=29 |
LMIC (%)
n=24 |
| Molecular testing recommended | 19/29 (66) | 9/24 (38) |
| Sampling recommended for all relevant anatomical sites* | 18/29 (62) | 8/24 (33) |
| Recommended screening frequency | ||
| Every 3 months | 17/29 (59) | 13/24 (54) |
| Every 3–6 months | 6/29 (21) | 3/24 (13) |
| Every 6 months | 4/29 (14) | 6/24 (25) |
| Other | 0/29 (0) | 1/24 (4) |
| Frequency not specified | 1/29 (3) | 1/24 (4) |
*Urethra, vaginal/cervix, anorectum and oropharynx, as applicable.
CT, Chlamydia trachomatis; HIC, high-income country; LMIC, low-income and middle-income country; NG, Neisseria gonorrhoeae; PrEP, pre-exposure prophylaxis.